Li Wen-Chun, Fan Shou-Zen
ADN, RN, Department of Anesthesiology, National Taiwan University Hospital, Taiwan, ROC.
MD, Attending Physician, Department of Anesthesiology, National Taiwan University Hospital., Taiwan, ROC.
Hu Li Za Zhi. 2019 Feb;66(1):107-114. doi: 10.6224/JN.201902_66(1).13.
AADC deficiency is a rare autosomal recessive disease that may lead to movement disorder and/or autonomic dysfunction. The prognosis of AADC deficiency patients is poor, and most die in childhood. Gene therapy is the only method currently available to help alleviate related symptoms. Gene therapy involves the injection of adeno-associated viral (AV) vector into the basal ganglia of patients, helping transfer the AADC gene and leading to improved AADC production and higher numbers of neurotransmitters in the brain. Moreover, as patients are unable to produce catecholamine, they may also suffer from a disorder affecting the regulatory control of the autonomic nervous system, resulting in hypoglycemia, which often causes imbalances in thermoregulation and hemodynamic and functional adjustments during surgery. Furthermore, the use of analgesics and inhalational anesthetics increase the risks of hypotension and bradycardia. Thus, in addition to assessing cardiac and respiratory system functions, it is important to evaluate the patient's airway before administering anesthesia, as structural anomalies or other situations may be present that lead to difficulties in tracheal intubation. Various airway tools, anesthesia equipment, and alternative plans should thus be prepared to protect the airway and maintain vital signs. All of the abovementioned issues increase the risks of AADC deficiency patients undergoing general anesthesia. The development of gene transfection for genetic diseases is a future trend. This paper identifies possible problems and related responses in perioperative patient care during gene therapy. The authors hope that these experiences provide references for the administration of AADC and similar gene therapies in the future.
芳香族氨基酸脱羧酶(AADC)缺乏症是一种罕见的常染色体隐性疾病,可能导致运动障碍和/或自主神经功能障碍。AADC缺乏症患者的预后较差,多数在儿童期死亡。基因治疗是目前唯一可用于缓解相关症状的方法。基因治疗包括将腺相关病毒(AV)载体注入患者的基底神经节,帮助转移AADC基因,从而提高AADC的产生量,并使大脑中的神经递质数量增加。此外,由于患者无法产生儿茶酚胺,他们可能还患有影响自主神经系统调节控制的疾病,导致低血糖,这在手术期间常常会引起体温调节、血流动力学和功能调节的失衡。此外,使用镇痛药和吸入性麻醉剂会增加低血压和心动过缓的风险。因此,除了评估心脏和呼吸系统功能外,在实施麻醉前评估患者的气道也很重要,因为可能存在导致气管插管困难的结构异常或其他情况。因此,应准备各种气道工具、麻醉设备和替代方案,以保护气道并维持生命体征。上述所有问题都增加了AADC缺乏症患者接受全身麻醉的风险。针对遗传疾病的基因转染技术的发展是未来的趋势。本文确定了基因治疗期间围手术期患者护理中可能出现的问题及相关应对措施。作者希望这些经验能为未来AADC及类似基因治疗的实施提供参考。